Generic Name and Formulations:
Pegaptanib sodium 0.3mg/prefilled syringe; soln for oph intravitreous inj; preservative-free.
Valeant Pharmaceuticals, Inc
Indications for MACUGEN:
Treatment of neovascular (wet) age-related macular degeneration.
Give by intravitreous inj. 0.3mg once every 6 weeks into the eye to be treated.
Ocular or periocular infections.
Monitor for infection during week following inj (endophthalmitis possible). Monitor intraocular pressure and perfusion of optic nerve. Pregnancy (Cat.B). Nursing mothers.
Vascular endothelial growth factor (VEGF) inhibitor.
Anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbances, vitreous floaters, vitreous opacities, blepharitis, conjunctivitis, photopsia, bronchitis, diarrhea, dizziness, headache, nausea, UTI, others.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|